FREA Emerging Adults Registry
Summary
The Framework for Research in Emerging Adults (FREA) is an innovative research platform designed to bridge the existing gaps in our understanding of mental health issues affecting individuals aged 16 to 24. This age group is important because of the significant changes they experience during this phase of life, which can have a profound impact on their mental well-being.
This registry aims to expand the scope of research in this critical area, thereby enhancing the mental health services and therapeutic interventions available to young adults. By joining the FREA Registry, participants are required to complete their demographic information that is focused on their mental health.
Eligibility
Eligible ages: 16 to 24
Accepts healthy participants: Yes
Inclusion criteria:
1. 16-24 years of age.
2. Seeking support for mental health struggles.
3. Resides in Alberta
Exclusion criteria:
1. Is under 16 or over 24 years old.
2. Does not speak English.
3. Does not have an Alberta PHN.
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
theFREA@ucalgary.ca https://www.theFREA.ca/registry www.redcap.link/frea
Principal investigator:
Paul Arnold
Clinical trial:
No
REB-ID:
REB22-0478
External links